Future Oncology :
Genomic alterations have led to significant advances in advanced lung cancer therapy and benefit is now being sought in adjuvant and neoadjuvant settings. Read up on the latest lung cancer content with Future Oncology.
Genomic alterations have led to significant advances in advanced lung cancer therapy and benefit is now being sought in adjuvant and neoadjuvant settings. Read up on the latest lung cancer content with Future Oncology.
OPTYX is a multi-center, prospective, observational study designed to further understand the actual experience of patients with advanced prostate cancer treated with relugolix (ORGOVYX®), an…
OPTYX is a multi-center, prospective, observational study designed to further understand the actual experience of patients with advanced prostate cancer treated with relugolix (ORGOVYX®), an…
What challenges are associated with value-based oncology care and how can these be overcome?
Discover the strides being made to unravel the complexities of brain tumors in our latest interview with Karen Noble.
What challenges are associated with value-based oncology care and how can these be overcome?
Explore opportunities for women in neuro-oncology with Dr Macarena Ines De La Fuente who has been the co-chair of the SNO’s Women and Diversity Committee.
How can MRI-guided radiation therapy offer in terms of real-time insights into glioblastoma disease progression?
What challenges are associated with value-based oncology care and how can these be overcome?
Neuregulin 1 (NRG1) fusions are oncogenic drivers that have been detected in non-small-cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. NRG1…
eNRGy is a clinical trial of zenocutuzumab for cancer caused by NRG1 gene fusions. Find out more in our latest journal feature here.